Business
Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology
Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of
About this update from Greenwich Lifesciences, Inc.
[{"type":"text","content":"\n\nIdentifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence\n\n\nA positive baseline immune response to GP2 in 22.8% of 145 patients suggests an existing immune response to GP2 associated with residual disease, impending recurrence, or prior treatments\n\n\nDNA sequencing of relevant GP2 specific T cells at baseline and during GP2 treatment could lead to potential CAR-T cell drug candidates\n\n\nData further validates 0% metastatic breast cancer recurrence mechanism and reaffirms that GP2 is a natural antigen that should be the target of peptide and T cell based platform technologies\n\n\n STAFFORD, Texas--(BUSINESS WIRE)--\nGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the publication of a poster for the GP2 Phase IIb clinical trial at the San Antonio Breast Cancer Symposium 2021 (SABCS). The CEO of Greenwich LifeSciences, Snehal Patel, recorded an audio track providing an overview. The abstract can be viewed at the bottom of this press release. The full poster with figures, tables, and audio can be accessed or downloaded from the Company’s website here.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005502/en/Figures 1-2: Summary of 5 year GP2 Data Published to Date (Graphic: Business Wire)\nFigure 1 is the new data published yesterday evening at SABCS, which shows that GP2 immune response at baseline could be a prognosticator of cancer recurrence. The Phase IIb clinical trial enrolled HER2 positive patients, who received a standard course of trastuzumab after surgery, and HER2 low patients, who did not receive trastuzumab after surgery. A Delayed-Type Hypersensitivity (DTH) reaction was used to assess baseline in vivo immune responses to GP2 in patients prior to exposure to GP2 treatment or placebo.\n\nThe poster data can be summarized as follows:\n\n‒ It was observed that 22.8% or 33 patients of the 145 patients reacted to GP2 at baseline with a positive immune response, which is defined as an induration of 5 mm or greater in the baselin...